Polaryx Therapeutics Secures FDA Fast Track for PLX-200 in Rare Diseases
Paramus, New Jersey, USA, April 21, 2026 In a major regulatory advancement for rare disease therapeutics, Polaryx Therapeutics, Inc....
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Paramus, New Jersey, USA, April 21, 2026 In a major regulatory advancement for rare disease therapeutics, Polaryx Therapeutics, Inc....
